Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ \ Origin: Appendix 5 \ \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13$ 

ABN		
99 00	08 894 442	
We (t	he entity) give ASX the following	g information.
	t 1 - All issues ust complete the relevant sections (attac	h sheets if there is not enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Unlisted Options
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	50,000,000
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Unlisted options exercisable at 9.1 cents per share on or before 23 November 2020

Name of entity

LEPIDICO LTD

<sup>+</sup> See chapter 19 for defined terms.

Upon exercise each share issued will rank Do the \*securities rank equally 4 equally with existing fully paid ordinary in all respects from the +issue date with an existing +class of shares. quoted +securities? If the additional \*securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Nil – grant of incentive options. Issue price or consideration 5 6 Purpose of the issue Grant of incentive options. (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder 23 November 2017 resolution under rule 7.1A was passed Number of \*securities issued | Nil 6c without security holder approval under rule 7.1

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	40,000,000
6f	Number of *securities issued under an exception in rule 7.2	10,000,000
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1: 405,918,224 7.1A: 284,646,880 See Annexure 1 attached.
7	<sup>+</sup> Issue dates	23 November 2017
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	

<sup>+</sup> See chapter 19 for defined terms.

		Number		+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in	2,857,520,897		Ordinary Shares
	section 2 if applicable)			
		Number	+Class	
9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	6,500,000	exercise p	Options with orice of 1.5 cents and
		40,000,000	Unlisted exercise	Options with price of 1.815 cents ing 3 August 2018
		2,500,000	Unlisted exercise p	Options with price of 1.0 cents and 31 December 2018
		50,000,000	with exer	Incentive Options cise price of 9.1 cents iring 23 November
		50,000,000	Options v	Director Incentive with exercise price of s and expiring 31 r 2019
		25,000,000		Incentive Options cise price of 2.5 cents iring 31 December
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A		
Par	Part 2 - Pro rata issue			

required?

Is security holder approval N/A

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

12	Is the issue renounceable or non-renounceable?
13	Ratio in which the *securities N/A will be offered
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates N/A
15	<sup>+</sup> Record date to determine N/A entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has security holders who will not be sent new offer documents
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.
19	Closing date for receipt of N/A acceptances or renunciations
20	Names of any underwriters N/A
21	Amount of any underwriting fee N/A or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue $N/A$
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## **Part 3 - Quotation of securities — N/A**You need only complete this section if you are applying for quotation of securities

34	Type (tick	of <sup>+</sup> securities one)
(a)		<sup>+</sup> Securities described in Part 1
(b)		All other <sup>+</sup> securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Enti	ties tl	hat have ticked box 34(a)
Addi	tional	securities forming a new class of securities (N/A)
Tick to		e you are providing the information or
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
277		A copy of any trust dood for the additional tecquities

<sup>+</sup> See chapter 19 for defined terms.

# Entities that have ticked box 34(b) - N/A

38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another <sup>+</sup> security, clearly identify that other <sup>+</sup> security)		
		Number	<sup>+</sup> Class

Number and \*class of all \*securities quoted on ASX (including the \*securities in clause 38)

Number	<sup>+</sup> Class

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Alex New Date: 23 November 2017

(Company secretary)

Print name: Alex Neuling

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
		1,750,458,712		
Share Issue Unlisted Option Exercise Listed Option Exercises Listed Option Exercises Rights Issue Shortfall Issue	8/11/17  24/10/17  25/11/16  2/12/16  20/4/16 15/5/16	408,711,219 6,500,000 38,234 40,645 238,659,066 46,781,408 700,730,572		
	Share Issue Unlisted Option Exercise Listed Option Exercises Listed Option Exercises Rights Issue	Share Issue 8/11/17 Unlisted Option Exercise 24/10/17 Listed Option Exercises Listed Option Exercises 2/11/16 Exercises 2/12/16 Rights Issue 20/4/16		

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 10 04/03/2013

<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>	Issues ratified at 2017 AGM: <b>395,279,517</b>
Number of partly paid +ordinary securities that became fully paid in that 12 month period	-
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed	
It may be useful to set out issues of securities on different dates as separate line items	
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	-
"A"	2,846,468,801

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"			
"B"	0.15		
	[Note: this value canr	not be chan	ged]
<b>Multiply</b> "A" by 0.15			426,970,321
Step 3: Calculate "C", the amou that has already been used	Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	Underwriter fee settlement	Shares	11,052,096
• Under an exception in rule 7.2	Issue announced	Options	10,000,000
• Under rule 7.1A	10/10/17		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>			21,052,096
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
"C"			21,052,096
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1			
"A" x 0.15			426,9 <del>7</del> 0,321
Note: number must be same as shown in Step 2			
Subtract "C"			21,052,096
Note: number must be same as shown in Step 3			-
<i>Total</i> ["A" x 0.15] – "C"	[Note: this is the rema	aining place	<b>405,918,224</b> ment capacity

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
" <b>A</b> "	2,846,468,801	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	284,646,880	
Step 3: Calculate "E", the amount of 7.1A that has already been used	of placement capacity under rule	
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
Notes: This applies to equity securities – not		
just ordinary securities  Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed		
Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security		
<ul> <li>holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	Nil	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10  Note: number must be same as shown in Step 2	284,646,880
Subtract "E"  Note: number must be same as shown in Step 3	Nil
<b>Total</b> ["A" x 0.10] – "E"	284,646,880  Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.